Antiviral treatment for babies with hepatitis B
Treatments studied
Part of Infections clinical trials.
This study tests antiviral medicine in babies under 1 year old who have hepatitis B. The goal is to see if early treatment can help clear the virus and protect the liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be 1 year old or younger.
- Your baby must have tested positive for hepatitis B surface antigen (HBsAg) and HBV DNA.
- Your baby's liver enzyme (ALT) level must be no more than 5 times the normal upper limit, and your baby must not have jaundice (yellowing of skin or eyes).
- You (or the legal guardian) must be willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well antiviral medicines work in children with chronic hepatitis B. It may help doctors find better ways to treat children who are starting treatment or who have been on treatment for a while.
This study tests a medicine called peginterferon alfa-2b to see if it can help children with chronic hepatitis B achieve a functional cure, meaning the virus stays under control. If your child has hepatitis B, this treatment might improve their chances of clearing the infection.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.